These findings indicate that targeted therapy can sensitize tumors to immunotherapy by fostering a more inflamed and antigen-rich tumor microenvironment, providing a clear mechanistic basis for introducing PD-1 blockade therapy early alongside BRAF/MEK inhibition. Here, MAP2K7 is linked to neoplasm.